GBECAM 0115 – AMAZONA III | Prospective evaluation of breast cancer at Brazilian institutions – Project AMAZONA III
LACOG 0115 – LORELEI | A Phase II Randomized, Double-Blind, Parallel Cohort Study of Neoadjuvant Letrozole + GDC-0032 versus Letrozole + Placebo in Post-Menopausal Women with ER+/HER2- Primary Breast Cancer.
LACOG 0413 – Male Breast Cancer | Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study.
LACOG 0615 – LATINABreast | A study to observe patients characteristics, treatment patterns and outcomes in patients with newly diagnosed breast cancer in Latin America.
LACOG 2118 – ALEXANDRA/IMpassion 030 | A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.
PALLAS | A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer
LACOG 0119 | Multicenter retrospective database on prognostic and predictive factors in patients with neuroendocrine tumors
LACOG/GTG 1318 – CCA | A multicenter retrospective database on prognostic and predictive factors in patients with squamous cell carcinoma of the anus.
LACOG 1518 – Bladder Cancer Registry | Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America: Retrospective and Translational Multicenter Database
LACOG 0515 – Testicular Registry | Multicentric database of patients with germ cell tumor with the purpose of clinical and pathological characterization and evaluation of cancer treatment outcomes
LACOG 0217 – IRONMAN | Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer
LACOG 1818 – Prostate Cancer Registry | Survival outcomes in metastatic prostate cancer in the Brazilian population – analysis of individual characteristics and treatment modalities in different national health institutions
LACOG 0218 – Hercules | A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer
LACOG 0415 – APA in Prostate Cancer | Phase II randomized study of Abiraterone acetate plus ADT versus APALUTAMIDE versus Abiraterone and APALUTAMIDE in patients with advanced prostate cancer with non-castrate testosterone levels
LACOG 0519 – PEACE III | A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
LACOG 0215 – EVITA | Prospective evaluation of patients with uterine cervical cancer in Brazilian health institutions
LACOG 1018 – PALBO in Ovarian Cancer | Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer
LACOG 0116 – LATINO LUNG | Prospective epidemiological study of metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America
LACOG 0118 – RELANCE | Retrospective epidemiological study of Locally Advanced Non Small Cell Lung Cancer
LACOG 0417 – CNS MTX | Retrospective Analysis of Patients with Non-Small Cell Lung Cancer with Brain Metastasis
LACOG 0718 – PCI Project | Prospective Evaluation of a Decision Tool for Prophylactic Skull Radiotherapy in Small Cell Lung Cancer
LACOG 1918 | Patient Journey with advanced lung cancer positive for ALK fusion in Brazil
LACOG 2218 – PACIFIC BRAZIL | Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL)
LACOG 0619 | Characterization of patients with diffuse gliomas in Brazil
LACOG 1618 – Bone Metastasis Radiotherapy | Radioterapia com 5 frações de 4 Gyou 10 frações de 3 Gydiárias versus 2 frações de 8 Gycom uma semana de intervalo em pacientes com metástases ósseas complicadas: um ensaio multicêntrico controlado randomizado
